The company has not filed an annual or quarterly report since its Q1 FY2018 10-Q, filed Oct 27, 2017. Its latest SEC filing is a REVOKED from Jun 28, 2021.
10-Q for Q1 FY2018, filed Oct 27, 2017
The sections below describe the company as of the FY2017 annual report.
Develops a pharmaceutical treatment for obesity and symptoms of type two diabetes.
10-K for FY2017, filed Jul 5, 2017
No revenue was reported.
10-K for FY2017, filed Jul 5, 2017
It expects to sell its future drug through pharmacies, with payors billed when pharmacies make retail sales; research studies would be for biopharmaceutical and pharmaceutical companies.
10-K for FY2017, filed Jul 5, 2017
10-Q for Q1 FY2018, filed Oct 27, 2017
−$390.2KView ↗
From minerals to medicine
The business moved from exploring a Philippine gold claim to developing a pharmaceutical treatment for obesity and symptoms of type two diabetes.
10-K for FY2014, filed Apr 20, 2015 10-K for FY2017, filed Jul 5, 2017We were incorporated on July 17, 2007 under the laws of the State of Nevada. We are in the very early stages of exploration. Our company is…View ↗
We are a life science company focused on the development and commercialization of a pharmaceutical preparation to treat obesity and the…View ↗
Competes with Vivus and Orexigen
10-K for FY2017, filed Jul 5, 2017The combination of the drugs phentermine and topiramate (trade name Qsymia, formerly Qnexa) is a medication for the treatment of obesity…View ↗
Loading...
